CAS 10310-32-4|Tribenoside
Introduction：Basic information about CAS 10310-32-4|Tribenoside, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Tribenoside | ||
|---|---|---|---|
| CAS Number | 10310-32-4 | Molecular Weight | 478.57700 |
| Density | 1.19g/cm3 | Boiling Point | 618.9ºC at 760mmHg |
| Molecular Formula | C29H34O6 | Melting Point | / |
| MSDS | ChineseUSA | Flash Point | 328.1ºC |
Names
| Name | (3R,4R,5R)-5-[1,2-bis(phenylmethoxy)ethyl]-2-ethoxy-4-phenylmethoxyoxolan-3-ol |
|---|---|
| Synonym | More Synonyms |
Tribenoside BiologicalActivity
| Description | Tribenoside is a vasoprotective agent, can be used for the research of hemorrhoids. Tribenoside has mild anti-inflammatory, analgesic, and wound healing properties[1]. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Inflammation/Immunology |
| In Vitro | Tribenoside (1 nM-100 µM) exhibits cytotoxic effect against HeLa cells with the EC50 of 13.74 µM[2]. Cell Viability Assay[2] Cell Line: HeLa cells Concentration: 1 nM, 10 nM, 100 nM, 1 µM, 10 µM, 100 µM Incubation Time: 72 hours Result: Reduced HeLa cells viability in a dose-responsive manner. |
| In Vivo | Tribenoside (oral administration in doses of 500 and 1,200 mg/kg weekly) significantly decreases in the development of osteoporosis[3]. Animal Model: male C57 black mice[3] Dosage: 500 and 1,200 mg/kg weekly Administration: Oral administration Result: Led to a significant reduction in the overall arthrotic involvement. |
| References | [1]. Yamato Kikkawa, et al. The influence of Tribenoside on expression and deposition of epidermal laminins in HaCaT cells. Biol Pharm Bull. 2010;33(2):307-10. [2]. Yu-Chen Lo, et al. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential. Sci Rep. 2017 Sep 12;7(1):11261. [3]. G Wilhelmi, et al. Suitability of the C57 black mouse as an experimental animal for the study of skeletal changes due to ageing, with special reference to osteo-arthrosis and its response to tribenoside. Pharmacology. 1976;14(4):289-96. |
Chemical & Physical Properties
| Density | 1.19g/cm3 |
|---|---|
| Boiling Point | 618.9ºC at 760mmHg |
| Molecular Formula | C29H34O6 |
| Molecular Weight | 478.57700 |
| Flash Point | 328.1ºC |
| Exact Mass | 478.23600 |
| PSA | 66.38000 |
| LogP | 4.49630 |
| Vapour Pressure | 3.55E-16mmHg at 25°C |
| Index of Refraction | 1.59 |
| InChIKey | ULLNJSBQMBKOJH-VIVFLBMVSA-N |
| SMILES | CCOC1OC(C(COCc2ccccc2)OCc2ccccc2)C(OCc2ccccc2)C1O |
| Storage condition | -20°C |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >20 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 8,2748,1974
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 2600 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 8,2748,1974
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >20 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 8,2748,1974
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >30 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 8,2748,1974
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 3300 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 8,2748,1974
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >30 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 8,2748,1974 ** OTHER MULTIPLE DOSE TOXICITY DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 84 gm/kg/2W-I
- TOXIC EFFECTS :
- Liver - changes in liver weight
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 8,2789,1974
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 65 gm/kg/30D-I
- TOXIC EFFECTS :
- Liver - fatty liver degeneration Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 8,2748,1974
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 156 gm/kg/26W-I
- TOXIC EFFECTS :
- Liver - fatty liver degeneration Liver - changes in liver weight Endocrine - changes in adrenal weight
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 8,2772,1974
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 84 gm/kg/2W-I
- TOXIC EFFECTS :
- Liver - changes in liver weight Endocrine - changes in spleen weight Endocrine - changes in thymus weight
- REFERENCE :
- KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 8,2789,1974
Safety Information
| RIDADR | NONH for all modes of transport |
|---|
Articles25
More Articles| The influence of Tribenoside on expression and deposition of epidermal laminins in HaCaT cells. Biol. Pharm. Bull. 33(2) , 307-10, (2010) Tribenoside has been used clinically for hemorrhoidal disease associated with coagulation, inflammation, and wounds. However, the pharmacological mechanism of tribenoside activity has never been clear... | |
| [Test of potential antiarthritic drugs on spontaneous arthritis of mice]. Z. Rheumatol. 42(4) , 203-5, (1983) | |
| [Centella asiatica extract in venous pathology of the lower limbs and its evaluation as compared with tribenoside]. Minerva Cardioangiol. 30(4) , 201-7, (1982) |
Synonyms
| Tribenosido [INN-Spanish] |
| TBGF |
| Tribenzoside |
| Tribenosidum [INN-Latin] |
| Glivenol |
| ethyl-3,5,6-tri-O-benzyl-D-glucofuranoside |
| EINECS 233-687-2 |
| tribenoside |
| Glyvenal |
| Glyvenol |
